

**Translation**

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation  
February 10, 2026

**Notice Regarding the Recording of Extraordinary Profit  
(Gain on Sales of Investment Securities)**

On November 6, 2025, the Company announced extraordinary profit is expected to be posted stemming from the sale of investment securities in the "Notice Regarding Revisions to Consolidated Performance Forecast". The Company announces that the sale of these investment securities has been completed, resulting in a gain on sales of investment securities (Extraordinary Profit) in the consolidated cumulative third quarters (from April 1, 2025 to December 31, 2025) detailed below.

**1. Reason for the Sale**

To reduce cross-shareholdings and to enhance asset efficiency

**2. Details of the Sale**

- (1) Sold Shares: three types of Listed Securities
- (2) Sell-off Period: October 9, 2025 to December 8, 2025
- (3) Gain on Sales of Investment Securities: 15,449 million yen

**3. Outlook**

The gain on sales of investment securities mentioned above is recorded as an extraordinary profit in the consolidated financial results for the nine months ended December 31, 2025, announced today. The gain on sales of investment securities has been incorporated into the full-year consolidated performance forecast for fiscal 2025, which was announced on November 6, 2025. There are no revisions to the consolidated performance forecast currently. If any matters requiring disclosure arise, including other matters, we will promptly disclose them.

### **About the Alfresa Group**

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, and regenerative medicine-related business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.9 trillion for the fiscal year ended March 31, 2025. For more information, please see: <https://www.alfresa.com/eng/>